Targeting the Pathway or the Cytokine? First Network Meta-Analysis Incorporating Phase 3 Povorcitinib Data: Comparative Efficacy of JAK1 vs. IL-17 Inhibitors in Moderate-to-Severe Hidradenitis Suppurativa

Bimzelx (bimekizumab-bkzx) - UCB

Humira (adalimumab) - AbbVie

Cosentyx (secukinumab) - Novartis

povorcitinib (INCB54707) - Incyte

Rinvoq (upadacitinib) - AbbVie

Ayhan Ozan Özdemir 1; Alexander Jalali1; Georgios Nikolakis2

May 13, 2026